Tear concentration and safety of levofloxacin ophthalmic solution 1.5% compared with ofloxacin ophthalmic solution 0.3% after topical administration in healthy adult volunteers

Walters T., Rinehart M., Krebs W., Holdbrook M.

2010
Cornea

View publication

Therapeutic Area

Front of the eye (FOTE)
Categories

Clinical development

Affiliations

Keystone Research, Ltd., 5717 Balcones Drive, Austin, TX 78731, United States; Santen Inc., Napa, CA, United States

Related Publications

Efficacy and Tolerance of Nova22007 Versus Vehicle in Patients With Vernal Keratoconjunctivitis (NOVATIVE): A Phase II/III, Multicenter, Double-masked, Randomized Study of 0.05% Cyclosporine A and 0.1% Ophthalmic Cationic Emulsion Versus Vehicle in Patients With Vernal Keratoconjunctivitis

Leonardi A, Pisella PJ, Benítez-Del-Castillo JM, Amrane M, Ismail D, Doan S, Bremond-Gignac D.

Correlation between gene expression and clinical scores in vernal keratoconjunctivitis

Leonardi A, Cavarzeran F, Rosani U, Righetti G, Garrigue JS, Brun P.

Topical cyclosporine A cationic ophthalmic emulsion in paediatric vernal keratoconjunctivitis: pooled analysis of randomised NOVATIVE and VEKTIS trials

Leonardi A, Doan S, Aragona P, Amrane M, Ismail D, Montero J, Németh J, Bremond-Gignac D

View all Front of the eye (FOTE) publications

Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022